Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Open Access
- 19 September 2019
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 8, 1659
Abstract
Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.Keywords
This publication has 137 references indexed in Scilit:
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialEuropean Heart Journal, 2013
- Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular DiseaseJournal of the American Society of Nephrology, 2011
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic NephropathyJournal of the American Society of Nephrology, 2011
- Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and MicroalbuminuriaAn Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications CohortMicroalbuminuria Outcomes in Type 1 DiabetesArchives of internal medicine (1960), 2011
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseNew England Journal of Medicine, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- Lowering Blood Pressure Reduces Renal Events in Type 2 DiabetesJournal of the American Society of Nephrology, 2009
- First Morning Voids Are More Reliable Than Spot Urine Samples to Assess MicroalbuminuriaJournal of the American Society of Nephrology, 2009
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003